Riviciclib hydrochloride

Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively[1][2]. Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells[3].

Product Specifications

CAS Number

[920113-03-7]

Product Name Alternative

P276-00

UNSPSC

12352005

Target

Apoptosis; CDK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Riviciclib_hydrochloride.html

Concentration

10mM

Purity

99.08

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)

Smiles

[H]Cl.O=C1C=C(C2=CC=CC=C2Cl)OC3=C([C@@H]4CCN(C)[C@H]4CO)C(O)=CC(O)=C31

Molecular Formula

C21H21Cl2NO5

Molecular Weight

438.31

References & Citations

[1]Roskoski R Jr, Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.Pharmacol Res. 2016 May;107:249-275.|[2]Joshi KS, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6 (3) :918-25.|[3]Joshi KS, et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6 (3) :926-34.